Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.

Rossi, E., Schinzari, G., Tortora, G., Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment, <<JOURNAL FOR IMMUNOTHERAPY OF CANCER>>, 2020; 8 (2): e000952-N/A. [doi:10.1136/jitc-2020-000952] [https://hdl.handle.net/10807/232389]

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment

Rossi, Ernesto;Schinzari, Giovanni;Tortora, Giampaolo
2020

Abstract

Pneumonitis is a rare but serious adverse event caused by cancer immunotherapy. The diagnosis between COVID-19-induced pneumonia and immunotherapy-induced pneumonitis may be challenging in the era of COVID-19 outbreak. Some clinical symptoms and radiological findings of pneumonitis can be attributed to the coronavirus infection as well as to an immune-related adverse event. Identifying the exact cause of a pneumonitis in patients on treatment with immunotherapy is crucial to promptly start the most appropriate treatment. The proper management of immune checkpoint inhibitors for the risk of pneumonia must take into account a series of parameters. Accurate attention should be payed to symptoms like cough, fever and dyspnea during immunotherapy.
2020
Inglese
Rossi, E., Schinzari, G., Tortora, G., Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment, <<JOURNAL FOR IMMUNOTHERAPY OF CANCER>>, 2020; 8 (2): e000952-N/A. [doi:10.1136/jitc-2020-000952] [https://hdl.handle.net/10807/232389]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/232389
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 21
social impact